Farmak starts G-E insulin production

9 January 2006

Ukraine-based drugmaker Farmak has started producing genetically-engineered insulin, according to the Interfax news agency. Farmak's director general, Filia Zhebrovskaya, said the firm expects to receive orders for 400,000-450,000 bottles (each containing 100 doses) of its new insulin in 2006. Ukraine's Deputy Health Minister, Valentyn Snisar, said the Ministry purchased nearly 900,000 bottles (each of 40 doses) in 2005.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight